Oreste Davide Gentilini

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4544837/publications.pdf

Version: 2024-02-01

131 papers

9,546 citations

47 h-index 94 g-index

139 all docs

139 docs citations

times ranked

139

8418 citing authors

#	Article	IF	CITATIONS
1	Weekly Paclitaxel Administered During a Twin Pregnancy for Recurrent Breast Cancer: Case Report and Review of the Literature. Journal of Adolescent and Young Adult Oncology, 2022, 11, 632-636.	0.7	1
2	Oncoplastic breast consortium recommendations for mastectomy and whole breast reconstruction in the setting of post-mastectomy radiation therapy. Breast, 2022, 63, 123-139.	0.9	22
3	Axillary surgery after neoadjuvant therapy in initially node-positive breast cancer: international EUBREAST survey. British Journal of Surgery, 2022, 109, 857-863.	0.1	22
4	The Clinical and Pathological Profile of BRCA1 Gene Methylated Breast Cancer Women: A Meta-Analysis. Cancers, 2021, 13, 1391.	1.7	9
5	Surgical Management of the Axilla in Clinically Node-Positive Breast Cancer Patients Converting to Clinical Node Negativity through Neoadjuvant Chemotherapy: Current Status, Knowledge Gaps, and Rationale for the EUBREAST-03 AXSANA Study. Cancers, 2021, 13, 1565.	1.7	85
6	Fibrin Sealants and Axillary Lymphatic Morbidity: A Systematic Review and Meta-Analysis of 23 Clinical Randomized Trials. Cancers, 2021, 13, 2056.	1.7	4
7	PET/MRI for Staging the Axilla in Breast Cancer: Current Evidence and the Rationale for SNB vs. PET/MRI Trials. Cancers, 2021, 13, 3571.	1.7	10
8	Development of a novel nomogram-based online tool to predict axillary status after neoadjuvant chemotherapy in cN+ breast cancer: A multicentre study on 1,950 patients. Breast, 2021, 60, 131-137.	0.9	9
9	Knowledge gaps in oncoplastic breast surgery. Lancet Oncology, The, 2020, 21, e375-e385.	5.1	34
10	Avoiding Axillary Sentinel Lymph Node Biopsy after Neoadjuvant Systemic Therapy in Breast Cancer: Rationale for the Prospective, Multicentric EUBREAST-01 Trial. Cancers, 2020, 12, 3698.	1.7	33
11	Personalized Risk–Benefit Ratio Adaptation of Breast Cancer Care at the Epicenter of COVID-19 Outbreak. Oncologist, 2020, 25, e1013-e1020.	1.9	28
12	Changes in breast cancer management during the Corona Virus Disease 19 pandemic: An international survey of the European Breast Cancer Research Association of Surgical Trialists (EUBREAST). Breast, 2020, 52, 110-115.	0.9	63
13	The generalisability of randomised clinical trials: an interim external validity analysis of the ongoing SENOMAC trial in sentinel lymph node-positive breast cancer. Breast Cancer Research and Treatment, 2020, 180, 167-176.	1.1	9
14	Theoretical and practical knowledge curriculum for European Breast Surgeons. European Journal of Surgical Oncology, 2020, 46, 717-736.	0.5	12
15	Recommendations for triage, prioritization and treatment of breast cancer patients during the COVID-19 pandemic. Breast, 2020, 52, 8-16.	0.9	188
16	Surgical Management of Breast Cancer in Young Women., 2020,, 69-77.		0
17	Axillary observation alone versus sentinel node biopsy: past, present and future perspectives. Minerva Chirurgica, 2020, 75, 392-399.	0.8	3
18	Risk-Reducing Bilateral Salpingo-Oophorectomy for BRCA Mutation Carriers and Hormonal Replacement Therapy: If It Should Rain, Better a Drizzle than a Storm. Medicina (Lithuania), 2019, 55, 415.	0.8	14

#	Article	IF	CITATIONS
19	Sentinel node biopsy after primary systemic therapy in node positive breast cancer patients: Time trend, imaging staging power and nodal downstaging according to molecular subtype. European Journal of Surgical Oncology, 2019, 45, 969-975.	0.5	15
20	A gap analysis of opportunities and priorities for breast surgical research. Lancet Oncology, The, 2019, 20, e1.	5.1	1
21	Rare sites of breast cancer metastasis: a review. Translational Cancer Research, 2019, 8, S518-S552.	0.4	16
22	Axillary staging for breast cancer during pregnancy: feasibility and safety of sentinel lymph node biopsy. Breast Cancer Research and Treatment, 2018, 168, 551-557.	1.1	33
23	Current Status and Future Perspectives of Axillary Management in the Neoadjuvant Setting. Breast Care, 2018, 13, 337-341.	0.8	9
24	Is Axillary Sentinel Lymph Node Biopsy Required in Patients Who Undergo Primary Breast Surgery. Breast Care, 2018, 13, 324-330.	0.8	22
25	Oncoplastic Breast Consortium consensus conference on nipple-sparing mastectomy. Breast Cancer Research and Treatment, 2018, 172, 523-537.	1.1	84
26	Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial. Lancet Oncology, The, 2018, 19, 1385-1393.	5.1	342
27	Coping Mechanisms, Psychological Distress, and Quality of Life Prior to Cancer Genetic Counseling. Frontiers in Psychology, 2018, 9, 1218.	1.1	9
28	Robotic Nipple-sparing Mastectomy and Immediate Breast Reconstruction With Implant. Annals of Surgery, 2017, 266, e28-e30.	2.1	103
29	Ipsilateral axillary recurrence after breast conservative surgery: The protective effect of whole breast radiotherapy. Radiotherapy and Oncology, 2017, 122, 37-44.	0.3	37
30	ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3). Breast, 2017, 35, 203-217.	0.9	203
31	Sentinel node biopsy in early breast cancer. A review on recent and ongoing randomized trials. Breast, 2017, 36, 14-19.	0.9	22
32	Improved prognosis of young patients with breast cancer undergoing breast-conserving surgery. British Journal of Surgery, 2017, 104, 1802-1810.	0.1	14
33	Breast Cancer (Diagnosed) During Pregnancy: Adapting Recent Advances in Breast Cancer Care for Pregnant Patients., 2017,, 709-718.		O
34	Less is more. Breast conservation might be even better than mastectomy in early breast cancer patients. Breast, 2017, 35, 32-33.	0.9	43
35	Electron Beam Intraoperative Radiotherapy (ELIOT) in Pregnant Women with Breast Cancer: From in Vivo Dosimetry to Clinical Practice. Breast Care, 2017, 12, 396-400.	0.8	11
36	Surgical Treatment of Local Recurrence in Breast Cancer Patients. , 2017, , 349-356.		0

#	Article	IF	Citations
37	Contralateral risk reducing mastectomy in patients with sporadic breast cancer. Benefits and hazards. European Journal of Surgical Oncology, 2016, 42, 913-918.	0.5	9
38	Second international consensus guidelines for breast cancer in young women (BCY2). Breast, 2016, 26, 87-99.	0.9	142
39	Physical function of the upper limb after breast cancer surgery. Results from the SOUND (Sentinel) Tj ETQq1 1 0 42, 685-689.	.784314 r 0.5	gBT /Overlo <mark>ck</mark> 68
40	General Concepts on Surgical Management of Cancer During Pregnancy., 2016,, 29-39.		0
41	Breast Cancer in General Population. , 2015, , 331-351.		O
42	Loco-regional Breast Cancer Recurrences. , 2015, , 447-459.		0
43	Breast Cancer Diagnosed During Pregnancy. JAMA Oncology, 2015, 1, 1145.	3.4	169
44	Overall survival according to type of surgery in young (â‰#0 years) early breast cancer patients: A systematic meta-analysis comparing breast-conserving surgery versus mastectomy. Breast, 2015, 24, 175-181.	0.9	113
45	Second Axillary Sentinel Lymph Node Biopsy for Breast Tumor Recurrence: Experience of the European Institute of Oncology. Annals of Surgical Oncology, 2015, 22, 2372-2377.	0.7	39
46	Effect of Metformin on Breast Ductal Carcinoma <i>In Situ</i> Proliferation in a Randomized Presurgical Trial. Cancer Prevention Research, 2015, 8, 888-894.	0.7	23
47	Staging the Axilla in Early Breast Cancer. JAMA Oncology, 2015, 1, 1031.	3.4	35
48	Breast conservative surgery for well-differentiated ductal intraepithelial neoplasia: Risk factors for ipsilateral breast tumor recurrence. Breast, 2014, 23, 829-835.	0.9	9
49	Conservative surgery for ipsilateral breast tumor recurrence. Journal of Surgical Oncology, 2014, 110, 62-67.	0.8	23
50	Locoregional treatment of breast cancer during pregnancy. Gynecological Surgery, 2014, 11, 279-284.	0.9	48
51	First international consensus guidelines for breast cancer in young women (BCY1). Breast, 2014, 23, 209-220.	0.9	135
52	Long-term follow-up of 5262 breast cancer patients with negative sentinel node and no axillary dissection confirms low rate of axillary disease. European Journal of Surgical Oncology, 2014, 40, 1203-1208.	0.5	41
53	Prognostic relevance of peritumoral vascular invasion in immunohistochemically defined subtypes of node-positive breast cancer. Breast Cancer Research and Treatment, 2014, 146, 573-582.	1.1	9
54	Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23–01): a phase 3 randomised controlled trial. Lancet Oncology, The, 2013, 14, 297-305.	5.1	998

#	Article	IF	CITATIONS
55	Immediate breast reconstruction with expander in pregnant breast cancer patients. Breast, 2013, 22, 657-660.	0.9	46
56	Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial. Lancet Oncology, The, 2013, 14, 1269-1277.	5.1	677
57	The indocyanine green method is equivalent to the 99mTc-labeled radiotracer method for identifying the sentinel node in breast cancer: A concordance and validation study. European Journal of Surgical Oncology, 2013, 39, 1332-1336.	0.5	89
58	Pathological features and survival outcomes of very young patients with early breast cancer: How much is $\hat{a} \in \text{ce}$ young $\hat{a} \in \text{ce}$. Breast, 2013, 22, 1046-1051.	0.9	32
59	The effect of metformin on apoptosis in a breast cancer presurgical trial. British Journal of Cancer, 2013, 109, 2792-2797.	2.9	72
60	Metformin effects on cancer adjacent breast preneoplasia in a randomized pre-surgical trial Journal of Clinical Oncology, 2013, 31, 1517-1517.	0.8	0
61	Management of breast cancer during pregnancy: Results of a large registry from a single institution Journal of Clinical Oncology, 2013, 31, 589-589.	0.8	O
62	The biological features and prognosis of breast cancer diagnosed during pregnancy: A case-control study. Acta Oncol \tilde{A}^3 gica, 2012, 51, 653-661.	0.8	65
63	Mastectomy without radiotherapy: outcome analysis after 10Âyears of follow-up in a single institution. Breast Cancer Research and Treatment, 2012, 134, 1221-1228.	1.1	19
64	Sarcoma of the Breast: Outcome and Reconstructive Options. Clinical Breast Cancer, 2012, 12, 438-444.	1.1	39
65	Repeating Conservative Surgery after Ipsilateral Breast Tumor Reappearance: Criteria for Selecting the Best Candidates. Annals of Surgical Oncology, 2012, 19, 3771-3776.	0.7	65
66	Abandoning sentinel lymph node biopsy in early breast cancer? A new trial in progress at the European Institute of Oncology of Milan (SOUND: entinel node vs bservation after axillary ltraSou). Breast, 2012, 21, 678-681.	0.9	353
67	The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer. European Journal of Cancer, 2012, 48, 3355-3377.	1.3	237
68	Can we avoid axillary dissection in the micrometastatic sentinel node in breast cancer?. Breast Cancer Research and Treatment, 2012, 131, 819-825.	1.1	64
69	An urgent need to reduce re-operation rates after breast conserving surgery. Gland Surgery, 2012, 1, 159-60.	0.5	3
70	ecancermedicalscience. Ecancermedicalscience, 2011, 5, 204.	0.6	6
71	Influence of Margin Status on Outcomes in Lobular Carcinoma. Annals of Surgery, 2011, 253, 580-584.	2.1	15
72	Sentinel Lymph Node Biopsy in Multicentric Breast Cancer: Five-Year Results in a Large Series from a Single Institution. Annals of Surgical Oncology, 2011, 18, 2879-2884.	0.7	24

#	Article	IF	CITATIONS
73	Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes. Breast Cancer Research and Treatment, 2011, 127, 713-720.	1.1	98
74	Sentinel Lymph Node Biopsy in Early Breast Cancer: The Experience of the European Institute of Oncology in Special Clinical Scenarios. Breast Care, 2011, 6, 208-214.	0.8	13
75	Sentinel lymph node biopsy in pregnant patients with breast cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 78-83.	3.3	123
76	Pathological complete response after preoperative systemic therapy and outcome: relevance of clinical and biologic baseline features. Breast Cancer Research and Treatment, 2010, 124, 689-699.	1.1	65
77	Breast-conserving surgery in 201 very young patients (<35 years). Breast, 2010, 19, 55-58.	0.9	21
78	Must we always hunt for a sentinel node?. Breast, 2010, 19, 13.	0.9	O
79	Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer. Annals of Oncology, 2010, 21, 1974-1981.	0.6	202
80	Analysis of local and regional recurrences in breast cancer after conservative surgery. Annals of Oncology, 2010, 21, 723-728.	0.6	127
81	Male breast cancer. Future Oncology, 2010, 6, 985-991.	1.1	9
82	Quality indicators in breast cancer care. European Journal of Cancer, 2010, 46, 2344-2356.	1.3	180
83	Breast cancer in pregnancy: Recommendations of an international consensus meeting. European Journal of Cancer, 2010, 46, 3158-3168.	1.3	238
84	Biomarkers for Risk Assessment and Prevention of Breast Cancer. Current Cancer Drug Targets, 2009, 9, 482-499.	0.8	13
85	Unavoidable mastectomy for ipsilateral breast tumour recurrence after conservative surgery: patient outcome. Annals of Oncology, 2009, 20, 1008-1012.	0.6	34
86	Breast conservation and sentinel lymph node biopsy after neoadjuvant systemic therapy. Breast, 2009, 18, S90-S92.	0.9	12
87	Weekly epirubicin in the treatment of gestational breast cancer (GBC). Breast Cancer Research and Treatment, 2009, 115, 591-594.	1.1	68
88	Conservative surgery in patients with multifocal/multicentric breast cancer. Breast Cancer Research and Treatment, 2009, 113, 577-583.	1.1	91
89	Is Electron Beam Intraoperative Radiotherapy (ELIOT) Safe in Pregnant Women with Early Breast Cancer? In Vivo Dosimetry to Assess Fetal Dose. Annals of Surgical Oncology, 2009, 16, 100-5.	0.7	27
90	Breast-Conserving Surgery in BRCA1/2 Mutation Carriers: Are We Approaching an Answer?. Annals of Surgical Oncology, 2009, 16, 3380-3387.	0.7	89

#	Article	IF	Citations
91	The survival impact of the choice of surgical procedure after ipsilateral breast cancer recurrence. American Journal of Surgery, 2009, 198, 461-462.	0.9	2
92	Awareness Is the Key to Conquering Male Breast Cancer. Southern Medical Journal, 2009, 102, 677.	0.3	1
93	Oncological results of immediate breast reconstruction: long term follow-up of a large series at a single institution. Breast Cancer Research and Treatment, 2008, 112, 545-549.	1.1	99
94	When Sentinel Lymph Node is Intramammary. Annals of Surgical Oncology, 2008, 15, 1304-1308.	0.7	31
95	Can Axillary and Supraclavicular Radiotherapy be Avoided after Breast-Conserving Surgery and Axillary Dissection in Women with Multiple Involved Axillary Nodes?: Experience at the European Institute of Oncology. Tumori, 2008, 94, 52-58.	0.6	7
96	Breast Cancer During Pregnancy: Epidemiology, Surgical Treatment, and Staging., 2008, 178, 39-44.		4
97	Sentinel Lymph Node Biopsy in Male Patients with Early Breast Cancer. Oncologist, 2007, 12, 512-515.	1.9	103
98	When can a second conservative approach be considered for ipsilateral breast tumour recurrence?. Annals of Oncology, 2007, 18, 468-472.	0.6	38
99	Is avoiding post-mastectomy radiotherapy justified for patients with four or more involved axillary nodes and endocrine-responsive tumours? Lessons from a series in a single institution. Annals of Oncology, 2007, 18, 1342-1347.	0.6	9
100	Unnecessary axillary node dissections in the sentinel lymph node era. European Journal of Cancer, 2007, 43, 2664-2668.	1.3	22
101	Male Breast Cancer in a Young Patient Treated with Nipple-Sparing Mastectomy: Case Report and Review of the Literature. Tumori, 2007, 93, 118-120.	0.6	5
102	Second axillary sentinel node biopsy for ipsilateral breast tumour recurrence. British Journal of Surgery, 2007, 94, 1216-1219.	0.1	61
103	Sentinel lymph node biopsy is feasible even after total mastectomy. Journal of Surgical Oncology, 2007, 95, 175-179.	0.8	35
104	Radioguided localisation (ROLL) of non-palpable breast lesions and simultaneous sentinel lymph node biopsy (SNOLL): the experience of the European Institute of Oncology. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 957-958.	3.3	19
105	Sentinel lymph node biopsy in multicentric breast cancer. The experience of the European Institute of Oncology. European Journal of Surgical Oncology, 2006, 32, 507-510.	0.5	46
106	Surgical technique of intraoperative radiation therapy with electrons (ELIOT) in breast cancer: A lesson learned by over 1000 procedures. Surgery, 2006, 140, 467-471.	1.0	57
107	Ipsilateral breast tumor reappearance in patients treated with conservative surgery after primary chemotherapy. The role of surgical margins on outcome. Journal of Surgical Oncology, 2006, 94, 375-379.	0.8	23
108	Second Biopsy of Axillary Sentinel Lymph Node for Reappearing Breast Cancer After Previous Sentinel Lymph Node Biopsy. Annals of Surgical Oncology, 2005, 12, 895-899.	0.7	69

#	Article	IF	CITATIONS
109	Evaluation of recombinant human erythropoietin to facilitate autologous blood donation before surgery in anaemic patients with cancer of the gastrointestinal tract. British Journal of Surgery, 2005, 82, 1637-1640.	0.1	64
110	Breast cancer among HIV-infected patients: The experience of the European Institute of Oncology. Journal of Surgical Oncology, 2005, 91, 141-142.	0.8	17
111	Conservative Treatment of Breast Cancer: Its Evolution. Breast Cancer Research and Treatment, 2005, 94, 195-198.	1.1	27
112	Optimised lymphoscintigraphy in pregnant patients with breast cancer is safe. Annals of Oncology, 2005, 16, 674-675.	0.6	0
113	Safety of sentinel node biopsy in pregnant patients. Annals of Oncology, 2005, 16, 987.	0.6	12
114	Breast cancer diagnosed during pregnancy and lactation: biological features and treatment options. European Journal of Surgical Oncology, 2005, 31, 232-236.	0.5	62
115	A new option for early breast cancer patients previously irradiated for Hodgkin's disease: intraoperative radiotherapy with electrons (ELIOT). Breast Cancer Research, 2005, 7, R828-32.	2.2	28
116	Chemotherapy Is More Effective in Patients with Breast Cancer Not Expressing Steroid Hormone Receptors. Clinical Cancer Research, 2004, 10, 6622-6628.	3.2	333
117	Safety of sentinel node biopsy in pregnant patients with breast cancer. Annals of Oncology, 2004, 15, 1348-1351.	0.6	193
118	Sentinel node detection in pre-operative axillary staging. European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31, S46-S55.	3.3	29
119	Chemotherapy during pregnancy: what is really safe?. Lancet Oncology, The, 2004, 5, 398.	5.1	32
120	Axillary Sentinel Lymph Node Biopsy in Patients With Pure Ductal Carcinoma In Situ of the Breast. Archives of Surgery, 2003, 138, 309.	2.3	142
121	Crohn's disease clinical course and severity in obese patients. Clinical Nutrition, 2002, 21, 51-57.	2.3	202
122	Early postoperative enteral nutrition improves gut oxygenation and reduces costs compared with total parenteral nutrition. Critical Care Medicine, 2001, 29, 242-248.	0.4	309
123	Artificial Nutrition After Pancreaticoduodenectomy. Pancreas, 2000, 21, 344-351.	0.5	111
124	Erythropoietin in Cancer Surgery. Transfusion Alternatives in Transfusion Medicine, 2000, 2, 10-12.	0.2	2
125	Perioperative Immunonutrition in Patients Undergoing Cancer Surgery. Archives of Surgery, 1999, 134, 428.	2.3	307
126	Preoperative Oral Supplement With Immunonutrients in Cancer Patients. Journal of Parenteral and Enteral Nutrition, 1998, 22, 206-211.	1.3	56

#	Article	IF	CITATIONS
127	Enteral nutrition with supplemented arginine, glutamine, RNA, and I‰-3 fatty acids. Current Opinion in Critical Care, 1998, 4, i.	1.6	O
128	Radical oncologic surgery affects the circulatory levels of interleukin 10., 1997, 66, 244-247.		15
129	Increased interleukin-10 serum levels in patients with solid tumours. Cancer Letters, 1996, 104, 1-5.	3.2	144
130	Thymopentin Modulates Th1 and Th2 Cytokine Response and Host Survival in Experimental Injury. Journal of Surgical Research, 1996, 62, 197-200.	0.8	9
131	A Single Unit of Transfused Allogeneic Blood Increases Postoperative Infections. Vox Sanguinis, 1996, 71, 170-175.	0.7	44